ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.190,64
0,18%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7209
0,80%
Bitcoin
83.966,77
-0,20%
Brent Oil
71,745
-0,17%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. EyePoint Pharmaceuticals Inc (EYPT)

  7. EyePoint Pharmaceuticals Inc (EYPT) Notícias

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EYPT
DataHoraFonteTítuloCódigoCompanhia
20/03/202517:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
17/03/202508:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
06/03/202518:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/03/202509:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/03/202509:00GlobeNewswire Inc.EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202509:00GlobeNewswire Inc.EyePoint Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
26/02/202509:00GlobeNewswire Inc.EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025NASDAQ:EYPTEyePoint Pharmaceuticals Inc
25/02/202509:00GlobeNewswire Inc.EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
14/02/202520:37Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/02/202509:00GlobeNewswire Inc.EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary EndpointsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
30/01/202509:00GlobeNewswire Inc.EyePoint to Present at Guggenheim SMID Cap Biotech ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
13/01/202509:00GlobeNewswire Inc.EyePoint Provides Company Update and Anticipated Development Milestones for 2025NASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/01/202518:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/01/202509:00GlobeNewswire Inc.EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
17/12/202409:00GlobeNewswire Inc.EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202409:00GlobeNewswire Inc.EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
14/11/202417:10Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/11/202418:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/11/202409:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/11/202409:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/10/202417:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
30/10/202417:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
29/10/202422:47GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingNASDAQ:EYPTEyePoint Pharmaceuticals Inc
28/10/202418:14GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:EYPTEyePoint Pharmaceuticals Inc
28/10/202408:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular EdemaNASDAQ:EYPTEyePoint Pharmaceuticals Inc
24/10/202408:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
22/10/202416:24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/09/202408:00GlobeNewswire Inc.EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of DirectorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
19/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/08/202417:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EYPT

Seu Histórico Recente

TSX
Y
Yellow Pages
EU
AFRHU
Amundi Luxembourg
NASDAQ
ABMHJXX
Morgan Stanley Finance L...
TSXV
RMG
Rainmaker Resources Ltd.
BFNX
ETHUSD
Ethereum
TG
MFJ
Polynovo
LSE
GCOR
Frk Sus Grc Etf
EU
BCART
Biocartis Group NV
BOV
JSLG3
JSL ON
LSE
PT29
Adnoc Mur. 34s
GATE
MCASHUSDT
MCashChain
NASDAQI
PADSCNR
Benchmark Apartments and...
TSXV
VRW
LSE
HCHA
Hsbc Msci Cn Ac
BSTP
AMPEUR
Amp
LATK
ANKRBTC
Ankr Network
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios